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Abstract Tumour necrosis factor-K (TNF) is a pleiotropic
cytokine involved in many metabolic responses in both normal
and pathophysiological states. In spite of the fact that this
cytokine (also known as ‘‘cachectin’’) has been related to many
of the metabolic abnormalities associated with cachexia, recent
studies suggest that TNF may also have a central role in obesity
modulating energy expenditure, fat deposition and insulin
resistance. This review deals with the role of TNF in the control
of fat mass and obesity.
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1. Introduction
Obesity is a multifactorial syndrome representing one of the
most important pathological states in Western countries. It
therefore represents a highly expensive problem. This meta-
bolic state is associated with hypertension, atherosclerosis,
diabetes, cardiovascular problems and certain types of cancer.
Obesity is characterized by an increase in body fat stores
linked to a lack of control on food intake and/or energy ex-
penditure. Very recent experimental data have shown that fat
tissue plays a pivotal role in the control of its own mass.
Thus, adipose tissue is able to synthesize and release mole-
cules which are able to regulate food intake and energy ex-
penditure into the circulation, and therefore acts as an endo-
crine tissue. Among these compounds, leptin (the product of
the ob gene) and tumour necrosis factor-K (TNF) might play a
very important role. The aim of the present review is to sum-
marize the experimental evidence involving TNF in human
obesity.
2. TNF as a pleiotropic cytokine
Tumour necrosis factor-K (TNF) is a pleiotropic factor that
exerts a variety of e¡ects, such as growth promotion, growth
inhibition, angiogenesis, cytotoxicity, in£ammation, and im-
munomodulation [1]. This cytokine is synthesized mainly by
macrophages in response to invasive stimuli, as an active 26
kDa membrane-bound precursor that is cleaved proteolyti-
cally to a mature 17 kDa form with the prosequence polypep-
tide remaining associated to the membrane [2]. The peptide is
bioactive as a 51 kDa trimer, which can be recognized by two
di¡erent receptors, TNFR1 or p55 (55 kDa) and TNFR2 or
p75 (75 kDa). The human forms are known as p60 and p80
respectively, due to their slightly higher molecular weight. All
these receptors are dimeric membrane-bound glycosylated
proteins present in the majority of cellular types. In spite of
this, the proportion of the two receptors varies between the
di¡erent tissues. Interestingly, the a⁄nity of the cytokine is
higher for TNFR1 [3] in spite of the high homology that both
receptors show in the extracellular domain. In addition to
binding TNF, other cytokines can also bind to these recep-
tors, thereby conferring a high pleiotropic potential. Although
the exact biological functions of the two receptors are still not
fully understood, it has been suggested that TNFR1 plays an
important role in both the pro-in£ammatory and cytotoxic
responses [4], while the other receptor may act simply modu-
lating the response generated by TNFR1 [5]. Due to its high
a⁄nity for its receptors, TNF can either act in an autocrine or
paracrine way at low concentrations or in an endocrine fash-
ion when it is released in high concentrations.
In addition to the membrane-bound receptors, soluble
forms of the two receptors (corresponding to the extracellular
domains and generated by proteolysis) are found in healthy
individuals [6,7], and show a higher degree of a⁄nity for the
cytokine than the corresponding bound forms. When TNF is
bound to these soluble receptors, it can no longer interact
with the membrane forms and, therefore, it has been specu-
lated that the presence of the soluble forms may constitute a
way of regulating TNF actions [8]. Highly elevated concen-
trations of the soluble receptors are found in the course of
AIDS [9], endotoxinemia [10] or cancer [11], which suggests a
regulatory mechanism to counteract TNF production. Inter-
estingly, Hotamisligil et al. [12] have shown that TNFR2 is
overexpressed in adipose tissue of obese humans (with a
strong correlation with BMI, hyperinsulinaemia and TNF
mRNA levels in adipose tissue) and that the levels of the
soluble receptor (sTNFR2) are elevated six-fold in the obese
subjects as compared with the healthy controls. Conversely,
the same authors report no change for the TNFR1 mRNA
levels or circulating levels in the same group of patients. These
results suggest that TNFR2 may play a role in obesity by
modulating the actions of TNF. In addition, recent data
show that TNF is also synthesized in non-immune cells such
as muscle or adipose cells [13^15].
3. TNF induces important metabolic changes
In adipose tissue, TNF inhibits lipoprotein lipase synthesis
[16] as well as the synthesis of acetyl-CoA carboxylase [17],
fatty acid synthase [18], fatty acid-binding protein and glycer-
ol phosphate dehydrogenase [19], all these enzymes being in-
volved in fat synthesis. This cytokine also stimulates triacyl-
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glycerol degradation in the adipocyte by activating the hor-
mone-sensitive lipase [18]. Partly as a result of these metabolic
changes in adipose tissue and partly because it stimulates liver
lipogenesis [20] and hepatic VLDL production [21], TNF
causes a severe hypertriglyceridaemia. The high levels of the
cytokine found in cancer [22] and chronic infection, AIDS in
particular [23], could be related to the hypertriglyceridaemia
present in these patients.
Concerning carbohydrate metabolism, the results obtained
with experimental models are somewhat con£icting. It was
¢rst described that the cytokine increased glucose turnover
and utilization in peripheral tissues in vivo [24]. However,
TNF did not stimulate glucose utilization by rat epitrochlearis
muscle in vitro [25]. Similarly, glucose utilization was not in-
creased by TNF in isolated spleen cells or alveolar macro-
phages [25], suggesting that its action in vivo may not be
direct. Later in vitro studies seem to indicate that TNF causes
a decrease of insulin-induced glucose uptake in isolated cells
due to a decrease in glucose (GLUT4) transporters [26]. How-
ever, no such evidence has been found in vivo.
4. TNF and insulin resistance
Pathological situations associated with a high TNF produc-
tion show a state of peripheral insulin resistance. Among
them, endotoxemia, cancer and trauma are normally associ-
ated with increases in circulating TNF and peripheral insulin
resistance. Thus, the general clinical impression is that the
insulin dose for diabetic patients must be increased if infection
is present, thus suggesting an additional impairment to insulin
resistance [27] (Fig. 1). Lang and Dobrescu [28], using an
euglycemic clamp in septic rats (induced by injection of live
E. coli), found that the septic state induced peripheral insulin
resistance. It is well known that during infection there is a
stimulation of macrophage TNF production by means of ei-
ther LPS or other endotoxins released by the infecting agent.
In addition, chronic administration of TNF to rats induces
systemic insulin resistance [29]. Clinical administration of
TNF to healthy humans has been reported as reducing insulin
sensitivity by inducing hyperglycemia without lowering insulin
levels [30].
Thus, since NIDDM is characterized by profound insulin
resistance, TNF could also be responsible for this pathological
state. Measurement of gene expression and protein levels for
the cytokine in type II diabetic patients has con¢rmed this
hypothesis [13,14]. In addition, an elevated expression of
TNF was implicated in animal models of obesity and in the
insulin-resistant diabetes mellitus which accompanies the dis-
order. In four models of obesity and insulin-resistant diabetes
(the fa/fa obese Zucker rat, the ob/ob obese mice, the tub/tub
obese mice and the db/db obese diabetic mice), expression of
TNF mRNA in adipose tissue was induced, with correspond-
ing elevation of TNF protein both locally and systemically
[31]. Interestingly, in vitro studies using fully di¡erentiated
3T3-L1 adipocytes have shown that when the cells are ex-
posed to TNF they became insulin-resistant since insulin is
not able to stimulate hexose transport [26]. This appears to
be a consequence of a down-regulation in the expression of
GLUT4, the insulin-stimulable glucose transporter. This ob-
servation may explain why in the same kind of cells, incorpo-
ration of glucose into lipids is diminished after incubation
with supernatants of activated macrophages [18]. The same
authors reported that long-term treatment of 3T3-F442A adi-
pocytes with TNF led to down-regulation of the GLUT4
mRNA, and although no similar results have yet been re-
ported in humans, their results suggest that the cytokine could
be a key mediator of abnormal gene expression in obesity
diabetes syndromes and could a¡ect glucose homeostasis. In
the same study, in vivo administration of the human TNF
soluble receptor partially reversed the resistance to glucose-
stimulated glucose uptake, thus suggesting that TNF could be
one of the mediators of insulin resistance in several experi-
mental obesity models [32]. Kern et al. [13] have reported an
elevated expression of the TNF gene in the adipose tissue of
obese subjects, with a high correlation existing between the
levels of TNF mRNA, the body mass index and the circulat-
ing insulin levels. In the same study, however, there was no
correlation found when the patients had a BMI above 45 kg/
m2. This discrepancy illustrates the complexity of the ethiol-
ogy of the obesity syndrome in humans which can only be
fully understood by integrating di¡erent modulatory mecha-
nisms. Most interestingly, Saghizadeh et al. [15] have found
that the TNF gene is also overexpressed in skeletal muscle in
diabetic subjects, which further supports the role of the cyto-
kine in the induction of a generalized state of insulin resist-
ance.
Fig. 1. Impairment of insulin action by TNF. TNF generates a state
of multiple insulin resistance (liver, adipose, skeletal muscle) basi-
cally by decreasing insulin receptor (IR) and IRS phosphorylation
and therefore the insulin signalling cascade. The results are changes
in GLUT4 expression and the relevant metabolic alterations, such
as an increase in lipolytic rate or a decrease in LPL in adipose tis-
sue or a decrease in amino acid transport in skeletal muscle.
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Considerable attention is now being focused on the mech-
anism by which TNF induces resistance in the cascade of
insulin signal transduction, the mechanism for tissue-speci¢c
overexpression in the obese adipocyte, and the possibility that
interference with the pathway could be a new therapeutic
approach to abrogate insulin resistance and thereby obesity-
induced diabetes. Hofmann et al. [33] have shown an over-
expression of TNF mRNA and TNF receptors mRNA in
adipose tissue and muscle from a mouse model of non-insu-
lin-dependent diabetes mellitus, the obese KKAy mice. They
also observed that the elevated expression of TNF mRNA can
be partially reduced by oral administration of an insulin-sen-
sitizing drug. Hotamisligil et al. [34] have shown that TNF has
the ability to decrease the tyrosine kinase activity of the in-
sulin receptor (IR). Treatment of cultured murine adipocytes
with TNF was shown to induce serine phosphorylation of
insulin receptor substrate-1 (IRS-1) and convert IRS-1 into
an inhibitor of the insulin receptor tyrosine kinase in vitro,
thus indicating that TNF induces insulin resistance through
an unexpected action of IRS-1 attenuating insulin receptor
signalling. Similar results were obtained with other cellular
types such as hepatocytes [35,36], adipocytes [34,37], muscle
cells [38] and ¢broblasts [39,40]. It may thus be suggested that
TNF expression is involved in a physiological loop, perhaps
related to a limitation of obesity at the expense of promoting
insulin resistance [41].
In spite of the experimental data, clinical observations
based on blocking TNF action to counteract insulin resistance
do not support the e⁄cacy of this type of treatment. Thus
Ofei et al. [42], after treating obese NIDDM patients with a
monoclonal TNF antibody concluded that there was no re-
versal of insulin sensitivity or glycaemic control.
5. Has TNF a role in the control of adipose tissue mass?
In addition to the fact that both adipose and muscle tissue
from either obese or diabetic subjects overexpress the TNF
gene, the circulating levels of the cytokine are also corre-
spondingly elevated, thus suggesting that the action of the
cytokine is not just limited to the tissue where it is produced
[43^46]. Indeed, TNF may act as a local signal regulating, in
addition to insulin resistance, fat accumulation either directly
by means of modulating the expression and synthesis of key
enzymes in lipid accretion such as LPL [16] or hormone-sen-
sitive lipase [18] or, indirectly, by controlling the rate of leptin
secretion [47]. This molecule has been shown to have impor-
tant e¡ects on lipid metabolism in the adipocyte [48].
The etiology of human adiposity is complex and multifac-
torial and, on the basis of twin studies, is thought to have a
strong genetic component. Genetic studies using sibling pair
analysis have shown a linkage between a marker near the
TNF locus and body fat content in Pima Indians [49].
But, what is the mechanism that activates adipocyte TNF
mRNA synthesis during obesity? Bearing in mind that the
TNF is in fact a counteracting molecule that will act to limit
obesity, the adipocyte size could be involved. Other hormonal
factors (elevated in the serum of obese patients) are the levels
of insulin, IGF-1, glucocorticoids or other glucose-modi¢ed
proteins [50] and could indeed have a role. Very recently,
Morin et al. [51] have shown that diet fat content may in£u-
ence the levels of TNF mRNA in adipocytes. Indeed, Wistar
rats receiving isoenergetic diets but with a higher fat content
(45% vs. 12% in controls) showed a higher TNF gene expres-
sion in adipose tissue. It is worth mentioning here that West-
erterp [52] found a direct correlation between fat intake and
obesity in£uence in human subjects, therefore reinforcing a
possible role for ingested fat in modulating fat accumulation
in adipose tissue.
A very elegant approach to elucidating the role of TNF in
obesity consisted of generating obesity (either induced by diet
or by crossing the mice with ob/ob animals) in TNF-de¢cient
mice. Thus, Uysal et al. [53] generated obese mice with a
targeted null mutation in the gene encoding TNF and also
those encoding for the two TNF receptors. TNF-de¢cient
mice show a lower body weight and fat accumulation than
the wild-type. The absence of TNF resulted in signi¢cantly
improved insulin sensitivity in both diet-induced obese mice
and the ones related to the ob/ob model of obesity. These
results clearly indicate that TNF is an important mediator
of insulin resistance through its e¡ects on several important
sites of insulin action. Similarly Ventre et al. [54], also using
mice lacking TNF, concluded that the cytokine was involved
in the insulin sensitivity present in an hyperphagic model of
rodent obesity.
To understand the implication of TNF in obesity in hu-
mans, studies with a longitudinal design become necessary
where subjects with a low energy expenditure, a higher respi-
ratory quotient (indicating a lower lipid oxidation) or a lower
insulin sensitivity are followed for a long period of at least 10
years in a similar fashion to the studies carried out with the
Pima Indians [55]. The fact that TNF may interfere in either
of these three factors seems very attractive and therefore this
type of study could serve to de¢nitely conclude that TNF is
involved in the control of body weight in human populations,
both in health and disease, in this case, obesity.
6. Concluding remarks: TNF and leptin?
In conclusion, insulin resistance, associated with human
obesity, is basically due to both a decrease in the levels of
insulin-responsive glucose transporters and a decrease in the
signal transduction associated with the binding of insulin to
its receptors. It could be speculated that the generation of
insulin resistance represents a mechanism to counteract the
expansion of body fat [56] and therefore limits obesity. TNF
seems to have a main role in activating this mechanism. How-
ever, TNF cannot be considered as the sole mediator or
‘‘adipostat’’ involved in the regulation of adipose mass (Fig.
2). The relatively ancient concept of the ‘‘adipostat’’ refers to
the fact that the size of the body fat depot is sensed by the
central nervous system through a product of fat metabolism
circulating in the blood and a¡ecting energy balance by inter-
acting with the hypothalamus [57]. Many mediators have been
proposed as carrying out this important function [58]. How-
ever, it has not been until recently that the discovery of leptin
[59] caused a complete revolution in the ¢eld of body weight
control. Indeed the product of the ob gene is a protein of 16
kDa synthesized in adipose tissue and secreted into the blood-
stream. The molecule travels to the brain where it can act as a
ponderostat or adipostat signal informing the brain of the
adipose tissue mass, its main action resulting in the loss of
appetite. Actually, the word leptin comes from the Greek
‘‘leptos’’ which means thin. The ob/ob mice have a defect in
the production of this protein, resulting in hyperphagia and,
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consequently, obesity. In other experimental models, such as
the fatty rat, the production of the compound is normal but
there seems to be a defect in the brain receptor [60], whose
amino acid sequence indicates that it is similar to those found
in class I cytokine receptor family [61]. In humans, leptin
levels and production are correlated with fat mass and adipo-
cyte size [62] ; however, morbid obesity involves a certain de-
gree of leptin resistance, and leptin levels do not correlate with
BMI [63], as well as they do with other obese patients. Feed-
ing a high-fat diet results in an increase in leptin production;
conversely, weight decrease results in lower leptin levels [64].
In addition, leptin production is also under hormonal control,
insulin having a key role in its production. It seems that
hyperinsulinaemic-euglycaemic clamp in rats results in an in-
crease in leptin mRNA in adipose tissue [65]. In addition,
insulin causes an increase in leptin mRNA in cultured adipo-
cytes, indicating a direct e¡ect of the hormone on adipocyte
leptin synthesis [66]. Similar actions on leptin expression are
induced by glucocorticoids [67].
Taking TNF into consideration, we ¢nd very similar trends
to those observed with leptin. First, it is expressed and se-
creted by adipose tissue and can in£uence thermogenesis
and indirectly, possibly either via IL-1 or leptin [68], food
intake. On the other hand, TNF has a direct (possibly para-
crine) function in adipose tissue where it limits mass by stim-
ulating lipolysis and decreasing LPL activity. We now know
that leptin could have a similar function on lipid metabolism
in adipose tissue [69]. TNF can also travel to the brain and
in£uence hypothalamic function. One problem confronting
such a hypothesis is the presence of the blood-brain barrier.
However, a number of peripheral peptides, including angio-
tensin II, can rapidly a¡ect the hypothalamus through nerve
cells in the region of the circumventricular organs that lie
outside the blood-brain barrier [70]. Alternatively, signals
could be brought to the hypothalamus through nerve cells
in the region of vagal a¡erent axons. Indeed, the intracraneal
administration of cytokines results in a more e¡ective stimu-
lation of thermogenesis [71]. TNF thus exerts central actions
which are complementary to the peripheral e¡ects on tissues.
In addition, TNF administration results in an increase in cir-
culating leptin concentrations [68].
If TNF is a central adipostatic molecule involved in fat
mass and body weight control, what happens during obesity?
Firstly, there is an overexpression of the cytokine, which is
aimed at stopping the hypertrophy of the tissue. The para-
crine TNF action is thus aimed to decrease LPL activity and
increase lipolysis at the same time as it generates insulin re-
sistance (interfering with the entry of glucose into the cells)
which further hampers the enlargement of the adipose tissue.
Secondly, in obesity one should talk about a certain ‘‘TNF
resistance’’ since the TNF which is released from adipose
tissue does not seem to have a very important e¡ect on the
control of thermogenesis and food intake. Interestingly, Das-
combe et al. [72] have demonstrated that genetically obese rats
are not a¡ected to the same extent (in terms of food intake
decrease and increased BAT thermogenesis) as lean ones after
intracraneal injections of the cytokine.
Finally, it has to be taken into consideration that it is not
being suggested here that TNF is the sole adipostat; to the
contrary, it is being postulated that the control of the fat mass
is accomplished by di¡erent molecules (which signal to the
brain fat mass). Among these molecules involved in the adi-
postatic function, TNF and leptin have fundamental roles, the
former directly by in£uencing lipid metabolism and the later
probably only by being a satiation factor and an insulin-coun-
terregulatory hormone.
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